Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BT-114143 in Healthy Subjects
NCT07169240Phase 1Completed
- Sponsor
- ScinnoHub Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BT-114143 in hyperfibrinolysis and hemorrhage (12 arms), sponsored by ScinnoHub Pharmaceutical. Primary endpoint: Safety and tolerability of BT-114143 at Day 21. Started Feb 2023; status: completed.
02
Drugs
BT-114143
03
Conditions
hyperfibrinolysishemorrhage
Beyond the preview
Go deeper on NCT07169240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169240.